Membranous nephropathy
Conditions
Interventions
Intervention group:Cyclophosphamide oral combined with Shuli Fraction Formula, 1 dose per day (before-after control)
Sponsors
Dongzhimen hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: All patients were diagnosed with biopsy-proven positive MN or serum anti-PLA2R antibodies. Patients meet the following criteria prior to starting combination therapy: 1) age 18-80 years; 2) eGFR > 30ml/min/1.73m2 3) Pathologically confirmed membranous nephropathy (stage 1-4) or positive PLA2R antibody by renal biopsy; 4) Meet the diagnostic criteria for intermediate- and high-risk MND; Referring to the 2024 KDIGO Clinical Management Guidelines for Glomerular Diseases and the Up to date guidelines the evaluation was carried out according to the temporal trend of clinical and serological parameters. 5) In patients who have received RASi for more than 3 months the amount of proteinuria is still > 3.5g/d; 6) No prior treatment with hormones and other immunosuppressants.
Exclusion criteria
Exclusion criteria: 1) Those who are pregnant lactating or have recently planned to become pregnant; 2) Indications for the need for corticosterol immunotherapy; 3) Other types of membranous nephropathy such as rapidly progressive membranous nephropathy (rapid loss of kidney function: 50% decrease in eGFR within 3 months) and secondary membranous nephropathy such as infections autoimmune diseases drugs tumors heavy metals etc.; 4) Use or are using steroid medications or other immunosuppressants in the past 6 months; 5) Heart failure abnormal liver function abnormal coagulation function and current infection; 6) Those who are allergic to the drug of this study; 7) Patients with severe mental illness or cognitive impairment who cannot cooperate with treatment; 8) malignant/uncontrolled hypertension; 9) Other causes of current renal instability such as acute kidney injury caused by massive hematuria; 10) White blood cell count < 3.0×109 /L or other blood disorders; 11) ECG showing prolonged QT interval or severe arrhythmias; 12) Concomitant administration of medications that can cause QT interval prolongation; 13) Patients who in the opinion of the supervising physician are unable to comply with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| anti-PLA2R;24hUTP;Alb;blood lipids;Scr; | — |
Countries
China
Contacts
Public ContactDuyiran
Dongzhimen hospital
Outcome results
None listed